Clinical modulation of epirubicin resistance by lonidamine in patients with advanced soft-tissue sarcomas

M. Lopez, S. Carpano, L. Di Lauro, L. Chiatti, P. Vici, F. Cavaliere, P. Gentile, G. Citro

Research output: Contribution to journalArticlepeer-review

Abstract

To determine if lonidamine (LND) could reverse anthracycline resistance in patients with advanced soft-tissue sarcomas, thirty-six patients were treated with epirubicin (EPI) 120 mg/m2 i.v. every 3 weeks. Progressive patients were given the same chemotherapy regimen on day 4 in combination with oral LND, 150 mg on day 1, 300 mg on day 2, and 450 mg on days 3, to 5. Among 35 evaluable patients there were 2 complete responses and 3 partial responses (PR) for an overall response rate of 14%. In the group treated with EPI+LND (24 evaluable patients) 2 PR were observed, lasting 3 and 10 months respectively. The overall survival was 11.5 months. The most common side-effects were myelotoxicity nausea and vomiting Clinical cardiotoxicity was, not observed. Only in one patient a 20% decrease in LVEF from baseline was recorded. LND related toxicities were mild to moderate myalgia and photophobia. In a pharmacokinetic study performed parallel to the clinical study, no difference was observed between the parameters derived from EPI and EPI+LND curves except for Vapp. This study indicates that LND may circumvent clinical resistance in some cases without altering chemotherapy related toxicity.

Original languageEnglish
Pages (from-to)363-367
Number of pages5
JournalInternational Journal of Oncology
Volume6
Issue number2
Publication statusPublished - 1995

Keywords

  • Epirubicin
  • Lonidamine
  • Multidrug resistance
  • Soft-tissue carcinoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint

Dive into the research topics of 'Clinical modulation of epirubicin resistance by lonidamine in patients with advanced soft-tissue sarcomas'. Together they form a unique fingerprint.

Cite this